Esperion Therapeutics, Inc.
ESPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $332 | $116 | $75 | $78 |
| % Growth | 185.7% | 54.1% | -3.8% | – |
| Cost of Goods Sold | $69 | $43 | $27 | $14 |
| Gross Profit | $264 | $73 | $49 | $64 |
| % Margin | 79.4% | 62.8% | 64.3% | 81.9% |
| R&D Expenses | $46 | $86 | $119 | $106 |
| G&A Expenses | $138 | $0 | $0 | $0 |
| SG&A Expenses | $163 | $143 | $109 | $185 |
| Sales & Mktg Exp. | $26 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $209 | $229 | $228 | $291 |
| Operating Income | $54 | -$156 | -$180 | -$227 |
| % Margin | 16.4% | -133.7% | -237.8% | -289% |
| Other Income/Exp. Net | -$106 | -$54 | -$54 | -$42 |
| Pre-Tax Income | -$52 | -$209 | -$234 | -$269 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$52 | -$209 | -$234 | -$269 |
| % Margin | -15.6% | -179.9% | -309.6% | -343% |
| EPS | -0.28 | -2.03 | -4.33 | -11.03 |
| % Growth | 86.2% | 53.1% | 60.7% | – |
| EPS Diluted | -0.28 | -2.03 | -4.33 | -11.03 |
| Weighted Avg Shares Out | 187 | 103 | 66 | 29 |
| Weighted Avg Shares Out Dil | 187 | 103 | 66 | 29 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $59 | $59 | $57 | $46 |
| Depreciation & Amortization | $0 | $0 | $1 | $1 |
| EBITDA | $8 | -$150 | -$176 | -$222 |
| % Margin | 2.3% | -129% | -233.7% | -283.2% |